Masitinib in Severe Indolent or Smoldering Systemic Mastocytosis Unresponsive to Optimal Symptomatic Treatment
Phase 3 Study to Compare Oral Masitinib to Placebo in Treatment of Patients With Smouldering or Indolent Severe Systemic Mastocytosis, Unresponsive to Optimal Symptomatic Treatment
Sponsor: AB Science
A PHASE3 clinical study on Indolent Systemic Mastocytosis, this trial is ongoing. The trial is conducted by AB Science and has accumulated 9 data snapshots since 2020. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE3
-
Jun 2025 — Sep 2025 [monthly]
Unknown PHASE3
Status: Recruiting → Unknown
-
Sep 2024 — Jun 2025 [monthly]
Recruiting PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE3
-
Jun 2023 — Jul 2024 [monthly]
Recruiting PHASE3
▶ Show 4 earlier versions
-
Dec 2021 — Jun 2023 [monthly]
Recruiting PHASE3
-
Jan 2021 — Dec 2021 [monthly]
Recruiting PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2020 — Dec 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AB Science
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Amiens, France , Berlin, Germany , Besançon, France , Bucharest, Romania , Dnipro, Ukraine , Gdansk, Poland , Grenoble, France , Krakow, Poland , Lille, France , London, United Kingdom and 7 more locations